Medyria develops the PyCath system, which provides cardiology clinicians with real-time physiological indices including coronary flow reserve (CRF) and fractional flow reserve (FFR), plus blood flow velocity via a proprietary sensor. The company is headquartered in Technopark Winterthur. Medyria plans to use its latest CHF 3.5 million financing to pursue FDA 510(k) clearance and to build commercial infrastructure in the United States as part of an international expansion. Prior financing includes CHF 1.5 million raised the previous year for PyCath development and a CHF 3.7 million Series B in 2018; the company also participated in Venture Kick in 2012 and was named a TOP 100 Swiss Startup in 2016. Management states the financing provides the runway to bring PyCath to U.S. physicians and improve patient treatment outcomes globally.

Total raised

$11M

Funding rounds

3

Latest round

Equity

Latest activity

Jul 2026